Phenotype
|
Fish
|
Conditions
|
Figures
|
trunk morphology, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5 ,
Fig. 8
from Amack et al., 2007
|
liver development decreased occurrence, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
Kupffer's vesicle malformed, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5 ,
Fig. 7
from Amack et al., 2007
|
determination of liver left/right asymmetry decreased occurrence, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
determination of pancreatic left/right asymmetry decreased occurrence, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
determination of left/right symmetry disrupted, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Amack et al., 2007
|
pancreas development decreased occurrence, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
pancreas development process quality, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
notochord kinked, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Amack et al., 2007
|
digestive system foxa3 expression spatial pattern, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
pancreas ins expression spatial pattern, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
determination of digestive tract left/right asymmetry decreased occurrence, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
pancreas position, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
diencephalon mislocalised, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Amack et al., 2007
|
liver position, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
whole organism sox32 expression decreased amount, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
pancreas ins expression decreased amount, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
Kupffer's vesicle decreased size, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5 ,
Fig. 7
from Amack et al., 2007
|
liver cp expression decreased amount, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
heart rudiment mislocalised, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Amack et al., 2007
|
digestive tract development process quality, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
whole organism mixl1 expression decreased amount, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
liver cp expression spatial pattern, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
post-vent region shape, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5 ,
Fig. 8
from Amack et al., 2007
|
endoderm sox17 expression decreased amount, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
liver development process quality, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
presumptive endoderm sox32 expression decreased amount, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
endodermal cell decreased amount, abnormal
|
AB + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
somite myod1 expression decreased distribution, abnormal
|
WT + MO3-tbx16
|
chemical treatment: Cyclopamine
|
Fig. 4
from Osborn et al., 2020
|
notochord posterior-most region fgf4 expression increased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
margin fgf8a expression increased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
notochord posterior-most region fgf3 expression increased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
notochord posterior-most region fgf8a expression increased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
presumptive paraxial mesoderm myod1 expression absent, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
tail bud myf5 expression decreased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
somite adaxial cell myf5 expression decreased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
tail bud myod1 expression absent, abnormal
|
WT + MO3-tbx16
|
chemical treatment: Cyclopamine
|
Fig. 4
from Osborn et al., 2020
|
adaxial cell myf5 expression absent, abnormal
|
WT + MO3-tbx16
|
chemical treatment: Cyclopamine
|
Fig. 4
from Osborn et al., 2020
|
axial chorda mesoderm fgf8a expression decreased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
segmental plate adaxial cell myod1 expression absent, abnormal
|
WT + MO3-tbx16
|
chemical treatment: Cyclopamine
|
Fig. 4
from Osborn et al., 2020
|
somite adaxial cell myod1 expression absent, abnormal
|
WT + MO3-tbx16
|
chemical treatment: Cyclopamine
|
Fig. 4
from Osborn et al., 2020
|
segmental plate adaxial cell myf5 expression decreased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
presumptive paraxial mesoderm myf5 expression decreased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
segmental plate adaxial cell myod1 expression decreased distribution, abnormal
|
WT + MO3-tbx16
|
standard conditions
|
Fig. 4
from Osborn et al., 2020
|
gut malformed, abnormal
|
ha01Tg + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
endoderm EGFP expression spatial pattern, abnormal
|
ha01Tg + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
digestive tract development process quality, abnormal
|
ha01Tg + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
endoderm EGFP expression decreased amount, abnormal
|
ha01Tg + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
determination of left/right asymmetry in lateral mesoderm process quality, abnormal
|
AB + MO1-fgf2 + MO3-tbx16
|
standard conditions
|
Fig. 5
from Arrington et al., 2013
|
post-vent region shape, abnormal
|
AB + MO1-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 8
from Amack et al., 2007
|
Kupffer's vesicle ciliated cell absent, abnormal
|
AB + MO1-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 8
from Amack et al., 2007
|
trunk morphology, abnormal
|
AB + MO1-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 8
from Amack et al., 2007
|
pancreas development decreased occurrence, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
whole organism sox32 expression decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
whole organism mixl1 expression decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
determination of digestive tract left/right asymmetry decreased occurrence, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
liver cp expression absent, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
anatomical structure cxcl12b expression decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
pancreas ins expression absent, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
liver development decreased occurrence, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
digestive tract development process quality, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
endoderm sox17 expression decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
whole organism gata5 expression decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
endodermal cell decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
presumptive endoderm sox32 expression decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
digestive system foxa3 expression spatial pattern, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
anatomical structure cxcl12a expression decreased amount, abnormal
|
AB + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|
determination of left/right asymmetry in lateral mesoderm process quality, abnormal
|
AB + MO3-tbx16 + MO5-sdc2
|
standard conditions
|
Fig. 5
from Arrington et al., 2013
|
gut malformed, abnormal
|
ha01Tg + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
endoderm EGFP expression spatial pattern, abnormal
|
ha01Tg + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
digestive tract development process quality, abnormal
|
ha01Tg + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 5
from Nelson et al., 2017
|
endoderm EGFP expression decreased amount, abnormal
|
ha01Tg + MO2-tbxta + MO3-tbx16
|
standard conditions
|
Fig. 4
from Nelson et al., 2017
|